实体瘤免疫治疗相关分离反应的研究进展
Research progress of dissociated responses related to immunotherapy for solid tumors
胡少聪1
作者信息
摘要
近年来,免疫检查点抑制剂(ICIs)在国内外临床实践中被广泛应用,极大改善了部分晚期恶性肿瘤患者的生存及预后.在接受免疫治疗后,一些患者体内会出现有反应病灶和无反应病灶共存的现象,即分离反应(DR).目前,DR的具体发生机制尚未阐明,评估标准各异,这给临床医师及时识别并治疗患者增加了挑战.本文就免疫治疗相关DR的定义及发生率、评估标准及潜在生物学机制等进行系统综述,以期为临床实践工作提供参考.
Abstract
In recent years,immune checkpoint inhibitors(ICIs)have been widely used in clinical practice at home and abroad,which have greatly improved the survival and prognosis of some patients with advanced malignant tumors.After immunotherapy,some patients will have a co-existence of responsive and non-responsive lesions,that is,dissociative reactions(DR).At present,the specific mechanism of DR has not been clarified,and the evaluation criteria vary,which increases the challenge for clinicians to identify and treat patients in a timely manner.In this paper,the definition,incidence,evaluation criteria and potential biological mechanisms of immunotherapy-related dissociated reactions are systematically reviewed in order to provide reference for clinical practice.
关键词
实体瘤/免疫检查点抑制剂/分离反应/免疫治疗Key words
Solid tumors/Immune checkpoint inhibitors/Dissociated responses/Immunotherapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据